{"id":"gabapentin-estrogen-and-placebo-administration","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Somnolence"},{"rate":null,"effect":"Peripheral edema"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Breast tenderness (estrogen-related)"}]},"_chembl":{"chemblId":"CHEMBL940","moleculeType":"Small molecule","molecularWeight":"171.24"},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Gabapentin, Estrogen and placebo administration","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T06:49:07.814694+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T06:49:24.986235+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T06:49:14.916373+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gabapentin, Estrogen and placebo administration","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T06:49:15.679858+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Voltage-gated calcium channel modulator","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T06:49:16.967304+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL940/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T06:49:16.867395+00:00"}},"_dailymed":null,"aiSummary":"Gabapentin, in combination with estrogen and placebo, is a marketed product developed by the University of Rochester. The key composition patent expires in 2028, providing a period of exclusivity and potential revenue protection. The primary risk is the lack of clear primary indication and key trial results, which may limit its market adoption and competitive positioning.","mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Gabapentin reduces neuronal excitability by binding to the alpha-2-delta subunit of voltage-gated calcium channels, thereby reducing neurotransmitter release. Estrogen provides hormonal replacement to address menopausal symptoms. The combination is being studied to determine whether gabapentin enhances estrogen's efficacy or provides additional benefit for hot flashes and related symptoms in postmenopausal women.","oneSentence":"This is a research combination of gabapentin (a gabapentinoid that modulates calcium channels) and estrogen (a hormone replacement therapy) tested together, likely to evaluate synergistic effects on vasomotor symptoms or neuropathic pain in menopausal women.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:47:00.111Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T06:49:24.986671+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"name":"Vasomotor symptoms (hot flashes) in menopausal women"},{"name":"Neuropathic pain in menopausal women (investigational)"}]},"trialDetails":[{"nctId":"NCT00276081","phase":"PHASE4","title":"Gabapentin Versus Estrogen for the Treatment of Hot Flashes","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2002-05","conditions":"Hot Flashes","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL940"},"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Gabapentin, Estrogen and placebo administration","genericName":"Gabapentin, Estrogen and placebo administration","companyName":"University of Rochester","companyId":"university-of-rochester","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T06:49:24.986671+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}